{'fraction_non_alphanumeric': 0.032679738562091505, 'fraction_numerical': 0.0010893246187363835, 'mean_word_length': 5.659420289855072, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Apolipoprotein A-I and B in laboratory diagnostics of dyslipidemia--what benefits do we gain compared with cholesterol measurements?].

Laboratory diagnostics of dyslipidemia has been based on serum total cholesterol, HDL- cholesterol, triglycerides, and calculated or direct LDL-cholesterol measurements. Apolipoprotein A-I (apoA-I) is the main protein in HDL particles, and apoB is the main protein in all other atherogenic lipoprotein particles. An increased number of apoB-containing lipoproteins with normal total and LDL-cholesterol is a common feature associated with obesity, metabolic syndrome, or type 2 diabetes. If the risk assessment of cardiovascular disease in these cardiometabolic disturbances is primarily based on LDL-cholesterol levels, the actual risk may be underestimated. Instead of cholesterol measurements, ApoA-Iand apoB measurements could produce more specific information on dyslipidemia.